What’s New with PD-L1 as a Companion Diagnostic?

Recorded On: 03/24/2021

Predictive biomarker testing to inform treatment decision-making has radically influenced the practice of both pathology and oncology today. As the treatment scenario evolves, choosing the appropriate biomarker to select the right patients become vital. In this talk we will review the most up-to-date FDA approvals for checkpoint inhibitors and PD-L1 companion diagnostic assays. We will then compare the different PD-L1 scoring systems (TPS, CPS, IC, TC) and point out the role of clinical validation of PD-L1 assays. Finally, we will look at the future of cancer targeted therapies and emerging biomarkers.

CEUs: This histology course is worth 1 continuing education credit. Course is available for 365 days from date of purchase.

Allie Cummings

Allie Cummings is a Technical Support Representative for Dako/Agilent. She received her Bachelors in Science from Texas A&M University and then went on to become a certified Histotechnologist in 2011. She began her career in Histology as a lab aide but after becoming a registered HT she moved to Dallas Children’s Hospital. At Dallas Children’s she was tasked with the challenge of evaluating and brining in a new IHC platform. She has been in her current role with Dako/Agilent for nearly 6 years.

Key:

Complete

Failed